These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 28567523)
1. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Tradtrantip L; Yao X; Su T; Smith AJ; Verkman AS Acta Neuropathol; 2017 Jul; 134(1):35-44. PubMed ID: 28567523 [TBL] [Abstract][Full Text] [Related]
2. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. Duan T; Smith AJ; Verkman AS J Neuroinflammation; 2018 Oct; 15(1):294. PubMed ID: 30348195 [TBL] [Abstract][Full Text] [Related]
3. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Duan T; Smith AJ; Verkman AS Acta Neuropathol Commun; 2019 Jul; 7(1):112. PubMed ID: 31296268 [TBL] [Abstract][Full Text] [Related]
4. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G. Yao X; Verkman AS Acta Neuropathol Commun; 2017 Feb; 5(1):15. PubMed ID: 28212662 [TBL] [Abstract][Full Text] [Related]
5. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Marignier R; Nicolle A; Watrin C; Touret M; Cavagna S; Varrin-Doyer M; Cavillon G; Rogemond V; Confavreux C; Honnorat J; Giraudon P Brain; 2010 Sep; 133(9):2578-91. PubMed ID: 20688809 [TBL] [Abstract][Full Text] [Related]
6. [Recent progress in multiple sclerosis research: astrocytopathy in demyelinating diseases]. Kira J Rinsho Shinkeigaku; 2010 Nov; 50(11):788-93. PubMed ID: 21921443 [TBL] [Abstract][Full Text] [Related]
7. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Tradtrantip L; Felix CM; Spirig R; Morelli AB; Verkman AS Neuropharmacology; 2018 May; 133():345-353. PubMed ID: 29428821 [TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196 [TBL] [Abstract][Full Text] [Related]
9. Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Yao X; Verkman AS Acta Neuropathol Commun; 2017 Jul; 5(1):57. PubMed ID: 28750658 [TBL] [Abstract][Full Text] [Related]
11. Role of membrane complement regulators in neuromyelitis optica. Saadoun S; Papadopoulos MC Mult Scler; 2015 Nov; 21(13):1644-54. PubMed ID: 25698168 [TBL] [Abstract][Full Text] [Related]
12. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309 [TBL] [Abstract][Full Text] [Related]
13. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Liu Y; Given KS; Harlow DE; Matschulat AM; Macklin WB; Bennett JL; Owens GP Acta Neuropathol Commun; 2017 Mar; 5(1):25. PubMed ID: 28340598 [TBL] [Abstract][Full Text] [Related]